October 12, 2017
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549-4561
| Attn: | Irene Paik |
| Re: | OncoCyte Corporation |
| Registration Statement on Form S-3 | |
| File No. 333-220769 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, OncoCyte Corporation hereby requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement to 4:00 p.m., Eastern Time, on Monday, October 16, 2017, or as soon thereafter as practicable.
Thank you for your assistance. Should you have any questions, please contact Andrew Ledbetter of DLA Piper LLP (US) at (206) 839-4845, or his colleague Kevin Criddle at (206) 839-4857.
Very truly yours,
OncoCyte Corporation
| /s/ William Annett | |
| William Annett | |
| President and Chief Executive Officer |